![]() ![]() ![]() The rise in incidence and prevalence of chronic eye disorders has prompted the medical research community to actively develop a variety of ophthalmic drugs / therapies. key geographical regions, covering North America (the US, Canada and Mexico), Europe (the UK, Germany, France, Spain, Italy and rest of Europe), and Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific).key disease indications (age-related macular degeneration, glaucoma, uveitis, dry eye, and other disease segments), and.company size (small sized, mid-sized, and large-sized companies),.scale of manufacturing (preclinical, clinical, and commercial),.type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, blister packing, and other forms),.type of FDF manufactured (solids, semi-solids, and liquids / suspensions),.In order to provide a detailed future outlook, projections have been segmented on the basis of: Based on various parameters, such as growth of the overall ophthalmic drugs market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. It is worth mentioning that the study primarily focuses on small molecule active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), including ophthalmic drops, emulsions, gels, injections, lotions, ointments, suspensions, and tablets / capsules. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030 features an extensive study of the contract services market for ophthalmic products and solutions. 20, 2020 (GLOBE NEWSWIRE) - The "Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030" report has been added to 's offering.Ĭurrent estimates indicate that the total economic burden related to vision loss is expected to reach approximately USD 384 billion by 2030, in the US alone ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |